BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

204 related articles for article (PubMed ID: 27965462)

  • 1. LEF1 reduces tumor progression and induces myodifferentiation in a subset of rhabdomyosarcoma.
    Dräger J; Simon-Keller K; Pukrop T; Klemm F; Wilting J; Sticht C; Dittmann K; Schulz M; Leuschner I; Marx A; Hahn H
    Oncotarget; 2017 Jan; 8(2):3259-3273. PubMed ID: 27965462
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Tumor suppressive functions of WNT5A in rhabdomyosarcoma.
    Ragab N; Bauer J; Uhmann A; Marx A; Hahn H; Simon-Keller K
    Int J Oncol; 2022 Sep; 61(3):. PubMed ID: 35796028
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Expression of insulin-like growth factor pathway proteins in rhabdomyosarcoma: IGF-2 expression is associated with translocation-negative tumors.
    Makawita S; Ho M; Durbin AD; Thorner PS; Malkin D; Somers GR
    Pediatr Dev Pathol; 2009; 12(2):127-35. PubMed ID: 18788888
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Constitutive activation of MET signaling impairs myogenic differentiation of rhabdomyosarcoma and promotes its development and progression.
    Skrzypek K; Kusienicka A; Szewczyk B; Adamus T; Lukasiewicz E; Miekus K; Majka M
    Oncotarget; 2015 Oct; 6(31):31378-98. PubMed ID: 26384300
    [TBL] [Abstract][Full Text] [Related]  

  • 5. PARsylated transcription factor EB (TFEB) regulates the expression of a subset of Wnt target genes by forming a complex with β-catenin-TCF/LEF1.
    Kim S; Song G; Lee T; Kim M; Kim J; Kwon H; Kim J; Jeong W; Lee U; Na C; Kang S; Kim W; Seong JK; Jho EH
    Cell Death Differ; 2021 Sep; 28(9):2555-2570. PubMed ID: 33753903
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Expression and activity of vascular endothelial growth factor and metalloproteinases in alveolar and embryonal rhabdomyosarcoma cell lines.
    Onisto M; Slongo ML; Gregnanin L; Gastaldi T; Carli M; Rosolen A
    Int J Oncol; 2005 Sep; 27(3):791-8. PubMed ID: 16077930
    [TBL] [Abstract][Full Text] [Related]  

  • 7. FOXM1 expression in rhabdomyosarcoma: a novel prognostic factor and therapeutic target.
    Kuda M; Kohashi K; Yamada Y; Maekawa A; Kinoshita Y; Nakatsura T; Iwamoto Y; Taguchi T; Oda Y
    Tumour Biol; 2016 Apr; 37(4):5213-23. PubMed ID: 26553361
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Hepatocyte growth factor activates Wnt pathway by transcriptional activation of LEF1 to facilitate tumor invasion.
    Huang FI; Chen YL; Chang CN; Yuan RH; Jeng YM
    Carcinogenesis; 2012 Jun; 33(6):1142-8. PubMed ID: 22436613
    [TBL] [Abstract][Full Text] [Related]  

  • 9. β-Catenin/LEF1 transactivates the microRNA-371-373 cluster that modulates the Wnt/β-catenin-signaling pathway.
    Zhou AD; Diao LT; Xu H; Xiao ZD; Li JH; Zhou H; Qu LH
    Oncogene; 2012 Jun; 31(24):2968-78. PubMed ID: 22020335
    [TBL] [Abstract][Full Text] [Related]  

  • 10. PAX7 is a required target for microRNA-206-induced differentiation of fusion-negative rhabdomyosarcoma.
    Hanna JA; Garcia MR; Go JC; Finkelstein D; Kodali K; Pagala V; Wang X; Peng J; Hatley ME
    Cell Death Dis; 2016 Jun; 7(6):e2256. PubMed ID: 27277678
    [TBL] [Abstract][Full Text] [Related]  

  • 11. PDK-1/AKT pathway as a novel therapeutic target in rhabdomyosarcoma cells using OSU-03012 compound.
    Cen L; Hsieh FC; Lin HJ; Chen CS; Qualman SJ; Lin J
    Br J Cancer; 2007 Sep; 97(6):785-91. PubMed ID: 17848913
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Global DNA methylation profiling uncovers distinct methylation patterns of protocadherin alpha4 in metastatic and non-metastatic rhabdomyosarcoma.
    Tombolan L; Poli E; Martini P; Zin A; Millino C; Pacchioni B; Celegato B; Bisogno G; Romualdi C; Rosolen A; Lanfranchi G
    BMC Cancer; 2016 Nov; 16(1):886. PubMed ID: 27842508
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Hedgehog/Patched-associated rhabdomyosarcoma formation from delta1-expressing mesodermal cells.
    Nitzki F; Cuvelier N; Dräger J; Schneider A; Braun T; Hahn H
    Oncogene; 2016 Jun; 35(22):2923-31. PubMed ID: 26387541
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Canonical WNT/β-Catenin Signaling Plays a Subordinate Role in Rhabdomyosarcomas.
    Ragab N; Viehweger F; Bauer J; Geyer N; Yang M; Seils A; Belharazem D; Brembeck FH; Schildhaus HU; Marx A; Hahn H; Simon-Keller K
    Front Pediatr; 2018; 6():378. PubMed ID: 30568936
    [TBL] [Abstract][Full Text] [Related]  

  • 15. MiR-218 reverses high invasiveness of glioblastoma cells by targeting the oncogenic transcription factor LEF1.
    Liu Y; Yan W; Zhang W; Chen L; You G; Bao Z; Wang Y; Wang H; Kang C; Jiang T
    Oncol Rep; 2012 Sep; 28(3):1013-21. PubMed ID: 22766851
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The transcription elongation factor TCEA3 induces apoptosis in rhabdomyosarcoma.
    Kazim N; Adhikari A; Oh TJ; Davie J
    Cell Death Dis; 2020 Jan; 11(1):67. PubMed ID: 31988307
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cinobufagin Suppresses Melanoma Cell Growth by Inhibiting LEF1.
    Kim GH; Fang XQ; Lim WJ; Park J; Kang TB; Kim JH; Lim JH
    Int J Mol Sci; 2020 Sep; 21(18):. PubMed ID: 32933177
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Deep Sequencing the microRNA profile in rhabdomyosarcoma reveals down-regulation of miR-378 family members.
    Megiorni F; Cialfi S; McDowell HP; Felsani A; Camero S; Guffanti A; Pizer B; Clerico A; De Grazia A; Pizzuti A; Moles A; Dominici C
    BMC Cancer; 2014 Nov; 14():880. PubMed ID: 25427715
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Artesunate induces ROS- and p38 MAPK-mediated apoptosis and counteracts tumor growth in vivo in embryonal rhabdomyosarcoma cells.
    Beccafico S; Morozzi G; Marchetti MC; Riccardi C; Sidoni A; Donato R; Sorci G
    Carcinogenesis; 2015 Sep; 36(9):1071-83. PubMed ID: 26153023
    [TBL] [Abstract][Full Text] [Related]  

  • 20. DNMT3B in vitro knocking-down is able to reverse embryonal rhabdomyosarcoma cell phenotype through inhibition of proliferation and induction of myogenic differentiation.
    Megiorni F; Camero S; Ceccarelli S; McDowell HP; Mannarino O; Marampon F; Pizer B; Shukla R; Pizzuti A; Marchese C; Clerico A; Dominici C
    Oncotarget; 2016 Nov; 7(48):79342-79356. PubMed ID: 27764816
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.